Format

Send to

Choose Destination
Pharmacogenomics J. 2014 Feb;14(1):14-9. doi: 10.1038/tpj.2012.54. Epub 2013 Jan 8.

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.

Author information

1
Medical Oncology Unit and Medical Genetics Unit, University Hospital of Parma, Parma, Italy.
2
Laboratory of Viral Immunopathology, Department of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy.
3
Clinical Microbiology Laboratory, Department of Laboratory Medicine, Santa Maria Nuova Hospital, Reggio Emilia, Italy.
4
Department of Radiology University Hospital of Parma, Parma, Italy.
5
Department of Oncology, IRCCS, Santa Maria Nuova Hospital, Reggio Emilia, Italy.
6
Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Pisa, Italy.
7
Department of Biomolecular Sciences, University of Urbino, Urbino, Italy.

Abstract

Antibody-dependent cellular cytotoxicity (ADCC), which is activated by effector cells via immunoglobulin G (IgG) fragment C receptors (FcRs), was proposed as a mechanism of cetuximab efficacy. Peripheral blood mononuclear cells (PBMCs) from 23 healthy donors and 13 patients with metastatic colorectal cancer (mCRC) treated with cetuximab were tested for FcγR polymorphisms and cetuximab-mediated ADCC. ADCC was measured by chromium-51 release on a epidermal growth factor receptor (EGFR)-positive human colon cancer cell line. Overall, 86 mCRC patients were genotyped for study purposes. PBMCs harbouring the FcγRIIIa 158 V/V genotype had a significantly higher cetuximab-mediated ADCC. No correlation was found between FcγR polymorphisms and response rate or time to progression after cetuximab-based therapy. Despite the in vitro analysis showing that the FcγRIIIa 158 V/V genotype is associated with higher ADCC, clinical data do not support a predictive role of FcγRIIIa polymorphisms in mCRC treated with cetuximab.

PMID:
23296156
DOI:
10.1038/tpj.2012.54
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center